Disarm Therapeutics hires Dr Alvin Shih as new President and CEO

pharmafile | July 23, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO.

The Cambridge, Mass.-based firm has set itself the task of creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central drive of neurological disease.

Dr Shih brings to the role a range of experiences. Having graduated with a biology degree from Vanderbilt University in 1996, Shih joined management consultancy McKinsey where he worked as a business analyst for two years.

In 1998 Shih decided to go to medical school in Alabama. While also studying for an MBA at Northwestern University’s Kellogg School of Management, Shih completed his medical degree at the University of Alabama’s School of Medicine, eventually graduating in 2003.

For the next three years Dr Shih would work as a resident physician at Massachusetts general hospital before going back to consultancy and joining LEK Consulting.

Finally in 2010 Dr Shih started his career in the pharmaceutical industry through joining Pfizer as the COO of the company’s Rare Disease Research Unit.

From Pfizer, Shih moved into the biotech space in taking on roles at Retrophin and Enzyvant where he was most recently CEO.

Jason Rhodes, partner with Atlas Venture and Disarm Co-founder and Board of Directors Chairman commented: “Disarm has created a powerful product engine and is advancing a new class of disease-modifying therapeutics for patients with diseases of the central, peripheral, and ocular nervous systems

“We are excited to welcome Alvin to Disarm. He brings exceptional leadership skills and biopharma experience to the company as we prepare for the next phase of growth and product development.”

Commenting on his own appointment, Dr Shih said: “Disarm’s work to understand and modulate SARM1, the central driver of axonal degeneration, has the potential to impact a broad range of diseases such as multiple sclerosis, ALS, and peripheral neuropathies. I’m excited to have the opportunity to lead a very talented team at Disarm as we work to develop transformative medicines for patients with neurological diseases.”

Related Content

No items found

Latest content